High expression of this TNFα/MCP-1 signature has been found to be associated with improved 5-year overall survival in ovarian carcinoma patients, suggesting that enhancement of this monocyte and macrophage axis may have significant clinical relevance [32]. This evidence concerns the gene CCL2 and ovarian carcinoma.